CLS-ACI-1 Cells

The CLS-ACI-1 cell line was established in 1998 from a solid mammary carcinoma, which was induced in a model organism through oral administration of 7,12-dimethylbenzo[a]anthracene (DMBA) at a dosage of 20 mg per kilogram body weight. DMBA is a well-known potent mutagen and carcinogen that is commonly used in experimental oncology for the induction of cancers, particularly in studies related to breast cancer. The establishment of the CLS-ACI-1 cell line from the tumor tissue allows for extensive in vitro exploration of breast cancer biology, particularly in understanding the mechanisms of carcinogenesis initiated by chemical agents like DMBA. In vitro studies using the CLS-ACI-1 cell line provide crucial insights into the cellular pathways and genetic alterations associated with mammary carcinomas. This cell line serves as a valuable tool for oncological research, including drug testing, resistance mechanisms, and cellular response to pharmacological agents. As a continuous cell line, CLS-ACI-1 offers a consistent and replicable model for studying the progression and treatment of breast cancer, facilitating the development of more effective therapeutic strategies against similar carcinomas induced by chemical agents in humans.